Data from our multivariable model suggests the likelihood of pCR is 12 times more likely in cancers <50 mm, albeit limited to HER2+ disease alone, vs. mixed molecular subtyping in Goorts’ analysis. The gene discussed is ERBB2; the disease is cancer.